Elite Pro en @eToro 🇪🇸 Analizo empresas y opino sobre ellas. Comparto mi cartera en abierto. ✍️ Substack: https://teapawt.net/t.co/EysU50qbwV
World
Joined November 2014
- Tweets11.2K
- Following563
- Followers3.8K
- Likes11.4K
Iván retweeted
Did it hit you that a centibillionaire, Jensen Huang, is less free than a random plumber?
🛵 Respecto al delivery de comida creo que tienen que elegir entre ser rentables y dar buen servicio, y eso es incompatible.
Si no puedes ser rentable dando buen servicio, tu futuro es negro. $UBER
$UBER Después de meses, hoy he vuelto a pedir Uber Eats para comer, la última vez va a ser.
Otra vez insisto en que está en la puta decadencia, el nivel del servicio al cliente es basura y encima caro.
Lo que antes tenías en 30 mins unas pizzas ahora tardan 1h y 21 minutos.
Y ya veremos si llega a las 14:41.
Parece que ahora entrega otros pedidos por el camino, osea que lo que te comes, te lo comes frío.
Si esto es el futuro de la comida a domicilio… no auguro nada bueno.
Ya puede invertir bien en comercios y supermercados... $UBER
4
5
845
Iván retweeted
1/
How $HIMS plans to disrupt healthcare with AI.
A thread, chart by chart
100X potential.
🧵
Iván retweeted
🚨🚨 Beautiful story. Real entrepreneurship masterclass.
Definitely has the look of a “we’re about to raise a few hundred million” post💰
Funny how they proudly show revenue per employee… but somehow never mention CAC or marketing as % of revenue.
Also hearing that a meaningful chunk of “their employees” aren’t actually on their payroll, so those costs conveniently sit outside the headcount math.
📈Anyway, good luck on the next raise.
They painted a very pretty picture.
I’m looking forward to them going public so we can properly compare the metrics with $HIMS
The @himshouse bears will be thrilled to switch over to Ro House the second it happens.
Makes me even more bullish on $HIMS now that @AndrewDudum is slamming the brakes on weight-loss marketing. When the meds are available everywhere, CAC gets brutal fast.
Iván retweeted
El próximo año $CHTR se va a cascar 8.5bn de FCF.
Actualmente el enterprise value son 126bn de los que el equity supone 19bn, es decir 2x FCF.
A eso le añadís que la compañía quiere bajar el apalancamiento de 3.9 a 3.5x (-11%), que serían 12bn menos de deuda para 2028.
Los bonos cotizan a 70centimos el dólar, y han dicho que van a destinar el FCF a la deuda. Veo super factible que en vez de 12bn, reduzcan el apalancamiento entre 20-30%.
Te quedas con 80-70bn de deuda.
A eso le añadís que los próximos 4 años van a generar probablemente 40-50bn de FCF, nos quedamos con 50bn de deuda neta.
Manteniendo el enterprise value en 126bn serían 76bn de equity value. Solo con eso es un 5x.
Además, la compañía está cotizando a 4.6x EBITDA de 2027, cuando históricamente ha cotizado a 8-10x.
A eso le añadís un crecimiento en ventas del 5-6% anual con expansión de márgenes (líneas móviles + pricing amplían margen) y crece al 7-9% el EBITDA.
Estarán haciendo para 2030 unos 36bn de EBITDA. A 8x eso son unos 300bn de enterprise value, le quitáis los 50bn de deuda neta, y os sale un equity value de 250bn.
Eso es un 13x los 19bn de ahora para 2030.
Todo esto, sin tener en cuenta toda la opcionalidad que hay si se meten fuerte en el negocio de networking para DCs que es lo que ya están haciendo.
Esto va a ser una barbaridad.
gutierrezcapitalresearch.sub…
$UBER Después de meses, hoy he vuelto a pedir Uber Eats para comer, la última vez va a ser.
Otra vez insisto en que está en la puta decadencia, el nivel del servicio al cliente es basura y encima caro.
Lo que antes tenías en 30 mins unas pizzas ahora tardan 1h y 21 minutos.
Y ya veremos si llega a las 14:41.
Parece que ahora entrega otros pedidos por el camino, osea que lo que te comes, te lo comes frío.
Si esto es el futuro de la comida a domicilio… no auguro nada bueno.
Ya puede invertir bien en comercios y supermercados... $UBER
🚨🚨 Beautiful story. Real entrepreneurship masterclass.
Definitely has the look of a “we’re about to raise a few hundred million” post💰
Funny how they proudly show revenue per employee… but somehow never mention CAC or marketing as % of revenue.
Also hearing that a meaningful chunk of “their employees” aren’t actually on their payroll, so those costs conveniently sit outside the headcount math.
📈Anyway, good luck on the next raise.
They painted a very pretty picture.
I’m looking forward to them going public so we can properly compare the metrics with $HIMS
The @himshouse bears will be thrilled to switch over to Ro House the second it happens.
Makes me even more bullish on $HIMS now that @AndrewDudum is slamming the brakes on weight-loss marketing. When the meds are available everywhere, CAC gets brutal fast.
Iván retweeted
My gut says Ro has been spending hard on GLP-1 marketing burning a ton of cash, and this article plus the podcast tour looks like groundwork for a raise. All the VC accounts cheering in the comments don't hurt that read.
If so, CAC is probably at levels that don't last. Andrew passed on that game with $HIMS shareholder money and chose to market a full membership with more value per dollar and better unit economics instead at a later date, done properly.
The recent $HIMS selloff likely makes any Ro raise harder too, since cheaper public comps mean more dilution.
The piece reads defensive to me. I think Andrew is playing a longer game than people give him credit for and is 10 steps ahead.
Ro seems to be locked in this year, and from this article I get the feeling they’re ramping up for an IPO.
It’s framed as lessons for founders, but read it closely and it’s a pitch. And the company it’s being measured against is never named. It’s $HIMS.
Why it reads like IPO prep:
- He says “there’s only one leader.” Leader compared to who? There’s really only one other player at this scale.
- The numbers he picked are run-rate, 3-year CAGR, revenue per employee, opex under 15%. That’s what you show bankers.
- He lists the companies doing $2B+ and growing 50%+ and says none are in healthcare. Except Ro. He wants to be valued like the AI labs, not a telehealth company.
- He answers “you’re just a GLP-1 company” and “you just rode a wave” before anyone asks. Those are the exact questions on an IPO roadshow.
What I didn’t see: gross margin, profitability, CAC, or how much of that revenue just flows through to Lilly and Novo. Also the $3B is November revenue times 12, not an actual year.
To be fair, going from where they were in 2021 to this with fewer people is really impressive.
But he calls Ro a steakhouse. Best at one thing.
Hims is building a Costco. Weight loss, hair, skin, sexual health, hormones, menopause, labs, genetics. Own pharmacies, own manufacturing, and now peptides and Lilly on top.
I think over time people go where one membership gives them the most for their money. Being great at one thing is a good business. Being the place people go for everything healthcare is a generational company that could be worth trillions.
Don’t mistake focus for a moat. Fitbit and Diapers.com were also very focused.
I own $HIMS, not advice.
🚨 $ABCL el 2027 será un año decisivo y apasionante!
-ABCL635: desarrollo clínico avanzado en menopausiay nuevos estudios para sofocos asociados a tratamientos de cáncer de mama y próstata.
- ABCL688 y ABCL386 podrían entrar en fase clínica.
Y tendremos datos adicionales de ABCL635 previstos para principios de año.
Se viene!
11
908
